Modified magnetic nanoparticles by PEG-400-immobilized Ag nanoparticles (Fe 3 O 4 @PEG-Ag) as a core/shell nanocomposite and evaluation of its antimicrobial activity
Zomorodian K., Veisi H., Mousavi SM., Ataabadi MS., Yazdanpanah S., Bagheri J.
Animal Study, published in Int J Nanomedicine (2018) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Int J Nanomedicine (2018)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 30022820
- PMCID
- PMC6042532
- DOI
- 10.2147/ijn.s161002
- Citations
- 28
Abstract (original English)
Background Noble metal nanoparticles, due to their good physicochemical properties, have been exploited in biological applications. Among these metals, nanosilver has attracted great attention because of its optical properties and broad-spectrum antimicrobial activities with no drug tolerance. Purpose The present study has attempted to conduct chemical synthesis of Fe 3 O 4 @PEG-Ag core/shell nanocomposites in aqueous solutions through co-precipitation of Fe 3+ and Fe 2+ ions, encapsulating the iron oxide core by poly (ethylene-glycol) (PEG) improve its hydrophilicity and biocompatibility, and immobilizing silver ions by application of NaBH 4 as a reducing agent. Patients and methods The synthesized structures were characterized by Fourier-transform infrared (FT-IR), field emission scanning electron microscopy, energy-dispersive X-ray spectrum, wavelength-dispersive X-ray, vibrating sample magnetometer, inductively coupled plasma-mass spectrometry and transmission electron microscopy methods. Antimicrobial activity of the nanostructures against Staphylococcus aureus , Escherichia coli and Candida albicans was evaluated by broth microdilution based on the methods suggested by Clinical Laboratory Standard Institute. Furthermore, the nanocomposite was tested for possible anti-parasitic effects against Leishmania major promastigotes by MTT assay. Also, its impacts on bacterial cell
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.